Main Inclusion Criteria:

          1. Written informed consent prior to admission to this study

          2. Female, aged ≥18 years

          3. ECOG performance status 0- 2

          4. Histologically confirmed invasive primary breast cancer

          5. Palpable breast tumour of any size, or tumour with an ultrasound or MRI size of at
             least 1.0 cm

          6. Haematologic and biochemical indices within the ranges shown below at the screening
             visit

               1. ANC 1500 cells/μl

               2. Platelet count 100000/μl

               3. Serum creatinine concentration < 1.5 x ULN

               4. Bilirubin level < 1.5 x ULN

               5. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x ULN

        Inclusion Criteria unique to the ER+ve cohort:

          1. ER+ve tumours defined as ≥1% of tumour cells positive for ER on IHC staining or an IHC
             score (Allred) of ≥3

          2. Postmenopausal defined as:

               1. Age 55 years and 1 year or more of amenorrhea

               2. Age 55 years and 1 year or more of amenorrhea with LH and/or FSH levels in the
                  postmenopausal range

               3. Age 55 with prior hysterectomy but intact ovaries with LH and/or FSH levels in
                  the postmenopausal range

               4. Status after bilateral oophorectomy ( 28 days prior to first study treatment)

        Inclusion Criteria unique to the AR+ve, TNBC cohort:

          1. AR positive tumours defined as any nuclear AR staining by IHC (enrolment may be based
             on local pathology findings; subsequent review of AR expression by central pathology
             laboratory will be carried out)

          2. Triple-negative tumours, i.e. tumour cells are negative for

               1. ER with <1% of cells positive on IHC or an IHC score (Allred) of ≤2

               2. PR with <1% of tumour cells positive on IHC or an Allred score of ≤2

               3. HER2 with 0, 1+ or 2+ intensity on IHC and no evidence of amplification of the
                  HER2 gene on ISH

          3. Negative serum or urine pregnancy test for women of childbearing potential within 2
             weeks prior to the first dose of study treatment, preferably as close to the first
             dose as possible. Patients of childbearing potential must agree to use adequate
             contraception (for example, intrauterine device [IUD], birth control pills unless
             clinically contraindicated, or barrier device) beginning 2 weeks before the first dose
             of investigational medicinal product (IMP) and for 30 days after the final dose of
             IMP.

        Exclusion Criteria:

          1. Inflammatory breast cancer

          2. Treatment with any of the following medications within 4 weeks before the baseline
             diagnostic biopsy is taken:

               1. Oestrogens, including hormone replacement therapy;

               2. Androgens (testosterone, dihydroepiandrosterone, etc.);

               3. Any approved or investigational agent that blocks androgen synthesis or targets
                  the AR (e.g., abiraterone acetate, ARN-509, bicalutamide, enzalutamide, ODM-201,
                  TAK-448, TAK-683, TAK-700)

          3. Previous systemic or local treatment for the new primary breast cancer currently under
             investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments);
             prior treatment for previous breast cancer or other neoplasms is allowed as long as it
             was completed at least 1 year prior to inclusion into this trial.

          4. History of seizure or any condition that may predispose to seizure; history of loss of
             consciousness or transient ischemic attack within 12 months before day 1.

          5. Significant cardiovascular disease, such as

               1. History of myocardial infarction, acute coronary syndromes or coronary
                  angioplasty/stenting/bypass grafting within the past 6 months.

               2. Congestive heart failure New York Heart Association (NYHA) Class III or IV or
                  history of congestive heart failure NYHA class III or IV, unless an
                  echocardiogram or multigated acquisition scan performed within 3 months before
                  day 1 reveals a left ventricular ejection fraction ≥ 45%;

               3. History of clinically significant ventricular arrhythmias (e.g., ventricular
                  tachycardia, ventricular fibrillation, torsade de pointes);

          6. Hypersensitivity to the active pharmaceutical ingredient or any of the excipients of
             the IMPs, including Labrasol, butylated hydroxyanisole, and butylated Hydroxytoluene

          7. Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of
             a disease or condition that contraindicates the use of an IMP, may affect the
             interpretation of the results, render the patient at high risk from treatment
             complications or interferes with obtaining informed consent.

          8. Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the study protocol.

          9. Concurrent treatment with other experimental drugs. Participation in another clinical
             trial with any investigational drug within 4 weeks prior to study entry.